These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34118242)

  • 21. Clinical evaluation of the antibody response in patients with COVID-19 using automated high-throughput immunoassays.
    Kubota K; Kitagawa Y; Matsuoka M; Imai K; Orihara Y; Kawamura R; Sakai J; Ishibashi N; Tarumoto N; Takeuchi S; Maesaki S; Maeda T
    Diagn Microbiol Infect Dis; 2021 Jul; 100(3):115370. PubMed ID: 33744623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal detection of SARS-CoV-2-specific antibody responses with different serological methods.
    Emmerich P; von Possel R; Hemmer CJ; Fritzsche C; Geerdes-Fenge H; Menge B; Messing C; Borchardt-Lohölter V; Deschermeier C; Steinhagen K
    J Med Virol; 2021 Oct; 93(10):5816-5824. PubMed ID: 34061367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance of the Roche/Snibe electrochemiluminescent anti-SARS-COV-2 spike assays compared to the Roche/Abbott IgG nucleocapsid and Abbott IgM spike assays.
    Lau CS; Wong MS; Hoo SP; Heng PY; Phua SK; Aw TC
    Pract Lab Med; 2021 Nov; 27():e00257. PubMed ID: 34660869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of 4 commercial assays for the detection of SARS-CoV-2 antibodies in a predominantly mildly symptomatic low prevalence Australian population.
    Wehrhahn MC; Brown SJ; Newcombe JP; Chong S; Evans J; Figtree M; Hainke L; Hueston L; Khan S; Marland E; O'Sullivan MVN; Powell H; Roy J; Waring L; Yu M; Robson J
    J Clin Virol; 2021 May; 138():104797. PubMed ID: 33770657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case-Control Study of Individuals with Discrepant Nucleocapsid and Spike Protein SARS-CoV-2 IgG Results.
    Wang H; Wiredja D; Yang L; Bulterys PL; Costales C; Röltgen K; Manalac J; Yee J; Zehnder J; Shi RZ; Boyd SD; Pinsky BA
    Clin Chem; 2021 Jul; 67(7):977-986. PubMed ID: 33720347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
    Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
    Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of commercial SARS-CoV-2 antibody assays, Jamaica.
    Butterfield TR; Bruce-Mowatt A; Phillips YZR; Brown N; Francis K; Brown J; Walker JP; McKnight NAL; Ehikhametalor K; Taylor DK; Bruce CA; McGrowder D; Wharfe G; Sandiford SL; Thompson TK; Anzinger JJ
    Int J Infect Dis; 2021 Apr; 105():333-336. PubMed ID: 33610776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers.
    Heaney CD; Pisanic N; Randad PR; Kruczynski K; Howard T; Zhu X; Littlefield K; Patel EU; Shrestha R; Laeyendecker O; Shoham S; Sullivan D; Gebo K; Hanley D; Redd AD; Quinn TC; Casadevall A; Zenilman JM; Pekosz A; Bloch EM; Tobian AAR
    J Clin Virol; 2021 Dec; 145():104997. PubMed ID: 34695724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance characteristics of five SARS-CoV-2 serological assays: Clinical utility in health-care workers.
    Heffernan E; Kennedy L; Hannan MM; Ramlaul N; Denieffe S; Courtney G; Watt A; Hurley J; Lynch M; Fitzgibbon M
    Ann Clin Biochem; 2021 Sep; 58(5):496-504. PubMed ID: 33845592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail.
    Egorov AI; Griffin SM; Fuzawa M; Kobylanski J; Grindstaff R; Padgett W; Simmons S; Hallinger DR; Styles JN; Wickersham L; Sams E; Hudgens E; Wade TJ
    Microbiol Spectr; 2021 Oct; 9(2):e0069321. PubMed ID: 34523986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
    Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
    Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
    Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
    Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19.
    Chiereghin A; Zagari RM; Galli S; Moroni A; Gabrielli L; Venturoli S; Bon I; Rossini G; Saracino IM; Pavoni M; Lafratta S; Deni A; Felici S; Borghi M; Guerra L; Raumer L; Lodi V; Viale P; Attard L; Lazzarotto T;
    Front Public Health; 2020; 8():620222. PubMed ID: 33681115
    [No Abstract]   [Full Text] [Related]  

  • 34. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.
    Mahmoud SA; Ganesan S; Naik S; Bissar S; Zamel IA; Warren KN; Zaher WA; Khan G
    Microbiol Spectr; 2021 Oct; 9(2):e0073321. PubMed ID: 34585943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Elecsys® Anti-SARS-CoV-2 and Elecsys® Anti-SARS-CoV-2 S antibody assays: Differentiating between vaccination and infection, and assessing long-term performance.
    Quee FA; Hogema BM; Molier M; Slot E; van den Hurk K; Zaaijer HL
    PLoS One; 2024; 19(7):e0305613. PubMed ID: 39024252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients.
    Muecksch F; Wise H; Batchelor B; Squires M; Semple E; Richardson C; McGuire J; Clearly S; Furrie E; Greig N; Hay G; Templeton K; Lorenzi JCC; Hatziioannou T; Jenks S; Bieniasz PD
    J Infect Dis; 2021 Feb; 223(3):389-398. PubMed ID: 33140086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
    Tang MS; Case JB; Franks CE; Chen RE; Anderson NW; Henderson JP; Diamond MS; Gronowski AM; Farnsworth CW
    Clin Chem; 2020 Dec; 66(12):1538-1547. PubMed ID: 32894750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization.
    Cameron A; Porterfield CA; Byron LD; Wang J; Pearson Z; Bohrhunter JL; Cardillo AB; Ryan-Muntz L; Sorensen RA; Caserta MT; Angeloni S; Hardy DJ; Zand MS; Pecora ND
    J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins.
    Favresse J; Cadrobbi J; Eucher C; Elsen M; Laffineur K; Dogné JM; Douxfils J
    J Med Virol; 2021 Apr; 93(4):2262-2269. PubMed ID: 33200836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.
    National SARS-CoV-2 Serology Assay Evaluation Group
    Lancet Infect Dis; 2020 Dec; 20(12):1390-1400. PubMed ID: 32979318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.